Keep eye on MRNS. It dropped 69% today due to the report that it's trial of treatment for drug-resistant epilepsy failed to meet goals and that it would discontinue the program and focus on other uses for the drug. The company said the trial of ganaxolone did not meet its primary endpoint in a trial of adults with drug-resistant focal onset seizures. The company will now focus on advancing ganaxolone for use in pediatric orphan indications and status epilepticus, a condition in which epileptic seizures follow one another without recovery of consciousness between them. It will provide a further update in coming weeks on its clinical programs.

We could see some recovery in a day or two.